Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $80.00 at SVB Leerink

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective decreased by research analysts at SVB Leerink from $85.00 to $80.00 in a report released on Thursday, Analyst Price Targets reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. SVB Leerink’s target price points to a potential upside of 33.33% from the stock’s current price. SVB Leerink also issued estimates for Enanta Pharmaceuticals’ Q1 2022 earnings at ($0.77) EPS, Q2 2022 earnings at ($1.07) EPS, Q3 2022 earnings at ($0.96) EPS and Q4 2022 earnings at ($0.82) EPS.

A number of other equities analysts also recently issued reports on the company. Robert W. Baird increased their target price on Enanta Pharmaceuticals from $71.00 to $130.00 and gave the stock an “outperform” rating in a research note on Monday, November 8th. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 10th. JMP Securities reaffirmed a “buy” rating and issued a $116.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 5th. Oppenheimer raised their price objective on Enanta Pharmaceuticals from $55.00 to $73.00 and gave the company a “market perform” rating in a research note on Wednesday, November 24th. Finally, Royal Bank of Canada dropped their price objective on Enanta Pharmaceuticals from $74.00 to $72.00 and set a “sector perform” rating for the company in a research note on Friday, November 19th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $89.00.

Shares of NASDAQ ENTA opened at $60.00 on Thursday. Enanta Pharmaceuticals has a 52-week low of $40.37 and a 52-week high of $102.00. The business has a 50-day moving average price of $78.71 and a 200 day moving average price of $63.78. The stock has a market cap of $1.22 billion, a PE ratio of -15.35 and a beta of 0.53.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 22nd. The biotechnology company reported ($1.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.31) by $0.09. The company had revenue of $23.58 million during the quarter, compared to analysts’ expectations of $35.65 million. Enanta Pharmaceuticals had a negative return on equity of 18.53% and a negative net margin of 81.38%. During the same period last year, the firm earned ($0.55) EPS. As a group, research analysts forecast that Enanta Pharmaceuticals will post -4.24 EPS for the current year.

In other news, VP Nathalie Adda sold 13,523 shares of the firm’s stock in a transaction on Wednesday, December 1st. The stock was sold at an average price of $86.35, for a total transaction of $1,167,711.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 35,606 shares of company stock worth $2,857,306 in the last 90 days. Insiders own 11.74% of the company’s stock.

A number of institutional investors have recently modified their holdings of ENTA. First Manhattan Co. boosted its holdings in Enanta Pharmaceuticals by 2,820.9% in the third quarter. First Manhattan Co. now owns 969,736 shares of the biotechnology company’s stock valued at $55,090,000 after acquiring an additional 936,536 shares during the last quarter. Armistice Capital LLC boosted its holdings in Enanta Pharmaceuticals by 21.4% in the second quarter. Armistice Capital LLC now owns 2,000,000 shares of the biotechnology company’s stock valued at $88,020,000 after acquiring an additional 352,000 shares during the last quarter. Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals by 490.2% in the second quarter. Millennium Management LLC now owns 140,742 shares of the biotechnology company’s stock valued at $6,194,000 after acquiring an additional 116,897 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Enanta Pharmaceuticals by 481.7% during the third quarter. Assenagon Asset Management S.A. now owns 95,149 shares of the biotechnology company’s stock worth $5,405,000 after purchasing an additional 78,792 shares in the last quarter. Finally, Krensavage Asset Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 8.9% during the second quarter. Krensavage Asset Management LLC now owns 939,650 shares of the biotechnology company’s stock worth $41,354,000 after purchasing an additional 76,802 shares in the last quarter. Hedge funds and other institutional investors own 95.40% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Featured Article: What is the strike price in options trading?

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.